People: Atara Biotherapeutics Inc (ATRA.OQ)

ATRA.OQ on NASDAQ Stock Exchange Global Select Market

2:29am IST
Change (% chg)

$0.11 (+0.46%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Touchon, Pascal 

Dr. Pascal Touchon serves as President, Chief Executive Officer, Director of the Company since June 2019. Prior to joining the Company, Dr. Touchon has served in roles of increasing responsibility at Novartis Oncology, a business unit of Novartis International AG, a global pharmaceutical company, since August 2015, most recently as Global Head Cell & Gene Therapies Oncology and a member of the Oncology Executive Committee. Previously, Dr. Touchon was Global Head Strategy, Business Development & Licensing, Oncology and a member of the Oncology Executive Committee. Prior to joining Novartis Oncology, Dr. Touchon spent nearly thirty years in the pharmaceutical industry in various companies, countries and leadership roles, most recently with Servier SAS, a privately owned French pharmaceutical company, as Senior Executive Vice President, member of the company Executive Committee and Head of Business Development and Licensing. Dr. Touchon holds a Doctorate in Veterinary Medicine from Paul Sabatier University (Toulouse, France), a Diplôme d’Etudes Supérieures Spécialisées (DESS) in Management from Institut d’Administration des Entreprises (Toulouse, France) and an MBA from INSEAD (Fontainebleau, France).

Basic Compensation

Total Annual Compensation, USD 654,118
Restricted Stock Award, USD 2,861,710
Long-Term Incentive Plans, USD --
All Other, USD 3,121,480
Fiscal Year Total, USD 6,637,310

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --